Literature DB >> 33676073

Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.

Ekaterina V Fedorova1, Carolyn F Wong2, Janna Ataiants3, Ellen Iverson4, Bridgid M Conn5, Stephen E Lankenau3.   

Abstract

INTRODUCTION: Cannabidiol (CBD) is purportedly a promising therapeutic agent to provide relief for a variety of medical conditions with mild or no psychoactive effects. However, little is known about young adults who use cannabis and CBD-dominant products, and associations between CBD use and other drug use.
METHODS: Young adults (aged 24-32) who currently used cannabis (n = 239) were surveyed in Los Angeles in March 2019 through March 2020. The sample was divided into CBD-dominant (at least 1:1 CBD:THC ratio) and THC-dominant product users. We described CBD forms, reasons and conditions for CBD use and examined between-group differences in sociodemographic characteristics, cannabis practices, health and other drug use.
RESULTS: CBD-dominant users were more likely to be female, use cannabis at lower frequency and amount (except for edible/drinkable/oral products), self-report medical motivation for cannabis use, use cannabis for pain and report more health problems. Oil, flower, topicals and sprays/drops/tinctures were the most prevalent CBD forms. Psychological problems and pain were commonly reported conditions and medical reasons for CBD use. CBD-dominant users were more likely to report illicit drug use, where psilocybin use was markedly different between the two groups.
CONCLUSIONS: CBD use was associated with health histories and motivations linked to pain and psychological problems. Positive association between CBD use and illicit drug use may indicate self-medication for psychological conditions. Future studies should evaluate the effectiveness of various CBD forms and dose regimens for treatment of pain and psychological problems, and as a potential intervention for decreasing other drug use and associated harms.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cannabidiol; Drug use; Medical marijuana; Young adults

Mesh:

Substances:

Year:  2021        PMID: 33676073      PMCID: PMC8462788          DOI: 10.1016/j.drugalcdep.2021.108648

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  52 in total

Review 1.  E-cigarette prevalence and correlates of use among adolescents versus adults: a review and comparison.

Authors:  Shawna L Carroll Chapman; Li-Tzy Wu
Journal:  J Psychiatr Res       Date:  2014-03-18       Impact factor: 4.791

Review 2.  In the weeds: a baseline view of cannabis use among legalizing states and their neighbours.

Authors:  Rosalie Liccardo Pacula; Mireille Jacobson; Ervant J Maksabedian
Journal:  Addiction       Date:  2016-01-26       Impact factor: 6.526

Review 3.  Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms.

Authors:  Gabriela Pandini Silote; Ariandra Sartim; Amanda Sales; Amanda Eskelund; F S Guimarães; Gregers Wegener; Samia Joca
Journal:  J Chem Neuroanat       Date:  2019-04-27       Impact factor: 3.052

4.  Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes.

Authors:  Meghan E Morean; Izzy R Lederman
Journal:  Addict Behav       Date:  2019-02-07       Impact factor: 3.913

5.  Narrative identity, rationality, and microdosing classic psychedelics.

Authors:  Megan Webb; Heith Copes; Peter S Hendricks
Journal:  Int J Drug Policy       Date:  2019-05-06

Review 6.  Cannabidiol (CBD) use in psychiatric disorders: A systematic review.

Authors:  Stefania Bonaccorso; Angelo Ricciardi; Caroline Zangani; Stefania Chiappini; Fabrizio Schifano
Journal:  Neurotoxicology       Date:  2019-08-11       Impact factor: 4.294

7.  Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi.

Authors:  Bill J Gurley; Timothy P Murphy; Waseem Gul; Larry A Walker; Mahmoud ElSohly
Journal:  J Diet Suppl       Date:  2020-05-20

8.  Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use.

Authors:  Zach Walsh; Robert Callaway; Lynne Belle-Isle; Rielle Capler; Robert Kay; Philippe Lucas; Susan Holtzman
Journal:  Int J Drug Policy       Date:  2013-09-09

9.  Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products.

Authors:  Tung Tran; Ramakanth Kavuluru
Journal:  Int J Drug Policy       Date:  2020-02-21

10.  Trends in Internet Searches for Cannabidiol (CBD) in the United States.

Authors:  Eric C Leas; Alicia L Nobles; Theodore L Caputi; Mark Dredze; Davey M Smith; John W Ayers
Journal:  JAMA Netw Open       Date:  2019-10-02
View more
  2 in total

1.  Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ).

Authors:  Katherine Walukevich-Dienst; Paige E Morris; Raymond P Tucker; Amy L Copeland; Julia D Buckner
Journal:  Psychol Assess       Date:  2022-03-17

2.  Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-06-30       Impact factor: 5.820

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.